mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO- KRK0109). This ...
SCOT: Tumor sidedness and the influence of chemotherapy duration on DFS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results